Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 1
1996 1
2004 1
2006 1
2010 1
2011 1
2014 1
2015 1
2018 3
2019 2
2020 3
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Soluble Guanylate Cyclase Stimulators and Activators.
Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP. Sandner P, et al. Among authors: milne gt. Handb Exp Pharmacol. 2021;264:355-394. doi: 10.1007/164_2018_197. Handb Exp Pharmacol. 2021. PMID: 30689085
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Hanrahan JP, de Boer IH, Bakris GL, Wilson PJ, Wakefield JD, Seferovic JP, Chickering JG, Chien YT, Carlson K, Cressman MD, Currie MG, Milne GT, Profy AT. Hanrahan JP, et al. Among authors: milne gt. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):59-69. doi: 10.2215/CJN.08410520. Epub 2020 Dec 16. Clin J Am Soc Nephrol. 2020. PMID: 33328269 Free PMC article. Clinical Trial.
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
Hanrahan JP, Seferovic JP, Wakefield JD, Wilson PJ, Chickering JG, Jung J, Carlson KE, Zimmer DP, Frelinger AL 3rd, Michelson AD, Morrow L, Hall M, Currie MG, Milne GT, Profy AT. Hanrahan JP, et al. Among authors: milne gt. Diabetologia. 2020 Apr;63(4):733-743. doi: 10.1007/s00125-019-05062-x. Epub 2019 Dec 19. Diabetologia. 2020. PMID: 31858186 Free PMC article. Clinical Trial.
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.
Hanrahan JP, Wakefield JD, Wilson PJ, Mihova M, Chickering JG, Ruff D, Hall M, Milne GT, Currie MG, Profy AT. Hanrahan JP, et al. Among authors: milne gt. Clin Pharmacol Drug Dev. 2019 Jul;8(5):564-575. doi: 10.1002/cpdd.627. Epub 2018 Nov 13. Clin Pharmacol Drug Dev. 2019. PMID: 30422390 Clinical Trial.
Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease.
Zimmer DP, Shea CM, Tobin JV, Tchernychev B, Germano P, Sykes K, Banijamali AR, Jacobson S, Bernier SG, Sarno R, Carvalho A, Chien YT, Graul R, Buys ES, Jones JE, Wakefield JD, Price GM, Chickering JG, Milne GT, Currie MG, Masferrer JL. Zimmer DP, et al. Among authors: milne gt. Front Pharmacol. 2020 Apr 8;11:419. doi: 10.3389/fphar.2020.00419. eCollection 2020. Front Pharmacol. 2020. PMID: 32322204 Free PMC article.
Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo.
Ranganath S, Bhandari A, Avitahl-Curtis N, McMahon J, Wachtel D, Zhang J, Leitheiser C, Bernier SG, Liu G, Tran TT, Celino H, Tobin J, Jung J, Zhao H, Glen KE, Graul C, Griffin A, Schairer WC, Higgins C, Reza TL, Mowe E, Rivers S, Scott S, Monreal A, Shea C, Bourne G, Coons C, Smith A, Tang K, Mandyam RA, Masferrer J, Liu D, Patel DV, Fretzen A, Murphy CA, Milne GT, Smythe ML, Carlson KE. Ranganath S, et al. Among authors: milne gt. PLoS One. 2015 Nov 10;10(11):e0141330. doi: 10.1371/journal.pone.0141330. eCollection 2015. PLoS One. 2015. PMID: 26555695 Free PMC article.
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.
Tobin JV, Zimmer DP, Shea C, Germano P, Bernier SG, Liu G, Long K, Miyashiro J, Ranganath S, Jacobson S, Tang K, Im GJ, Sheppeck J 2nd, Moore JD, Sykes K, Wakefield J, Sarno R, Banijamali AR, Profy AT, Milne GT, Currie MG, Masferrer JL. Tobin JV, et al. Among authors: milne gt. J Pharmacol Exp Ther. 2018 Jun;365(3):664-675. doi: 10.1124/jpet.117.247429. Epub 2018 Apr 11. J Pharmacol Exp Ther. 2018. PMID: 29643251
18 results